Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
DENVER, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Execution is the theme this morning, as a cluster of emerging growth names move from pilot programs and strategic roadmaps into operational scale. Kraig Biocraft Laboratories Moves from Plan to Production Kraig Biocraft Laboratories (OTCQB:KBLB) announced that its 2026 production strategy has officially shifted into execution mode, with bio-material moved into incubation ahead of its March production run. The company is targeting sustained monthly 10 metric-ton-level output of recombinant spider silk cocoons, an ambitious scale-up initiative in a niche but potentially transformative advanced materials market. CEO Kim Thompson characterized the d
Preferred model pricing and cutting-edge AI accelerate Art-Gen growth and global creator adoption Roseland, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced that it finalized a deal with Byteplus, the Enterprise Technology Division of ByteDance. Under the agreement, Gaxos will receive preferred pricing and significant discounts on ByteDance's cutting-edge video generation models, enabling faster deployment of AI capabilities inside Art-Gen, Gaxos' flagship AI image and video creation platform that makes pro-grade content effortless for anyone, anywh
Caylent Named Development Partner to Lead AWS-Native Build Roseland, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced that Amazon Web Services ("AWS") has committed to fund the preliminary development of Gaxos Labs' innovative, AI-powered sales coaching platform, positioning Gaxos to compete in the multibillion- dollar sales technology market. The AWS-backed initiative, in collaboration with Caylent, an AWS premier partner, supports the development of a real-time, AI sales platform designed for enterprise-scale deployment, incorporating live call t
4 - GAXOS.AI INC. (0001895618) (Issuer)
4 - GAXOS.AI INC. (0001895618) (Issuer)
4 - GAXOS.AI INC. (0001895618) (Issuer)
8-K - GAXOS.AI INC. (0001895618) (Filer)
424B5 - GAXOS.AI INC. (0001895618) (Filer)
424B5 - GAXOS.AI INC. (0001895618) (Filer)
Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell. "The addition of top medical talent to our Medical Advisory Board reflects our continued commitment to pursuing a best-in-class solution for Gaxos Health," said Vadim Mats, CEO of Gaxos.AI. "An advisory board of experts in their respective fields will allow to create a better product and advancing our mission of creating value for shareholders." Dr. Eric Margolis, M.D. is a Board-Ce
Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that it had acquired the rights to use certain AI-enabled technology from a top biohacking app, "Ultiself," in order to facilitate the development of its tech for Gaxos Health. The integration of Ultiself's proprietary technology into Gaxos Health's proposed product offering will enable enhanced customization and user experience aligning with modern-day consumer's demands for custom and efficient solutions. This move is expected to accelerate Gaxos Health's development and help solidify its positio
SC 13G - GAXOS.AI INC. (0001895618) (Subject)